

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT5551810

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
MICHAEL DOCKAL	04/29/2011
RUDOLF HARTMANN	04/29/2011
MARKUS FRIES	04/29/2011
FRIEDRICH SCHEIFLINGER	05/09/2011
HARTMUT EHRLICH	05/10/2011
RECEIVING PARTY DATA	
Name:	BAXTER INTERNATIONAL INC.
Street Address:	ONE BAXTER PARKWAY
City:	DEERFIELD
State/Country:	ILLINOIS
Postal Code:	60015
Name:	BAXTER HEALTHCARE SA
Street Address:	THURGAUERSTRASSE 130
City:	GLATTPARK (OPFIKON)
State/Country:	SWITZERLAND
Postal Code:	8152
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	16246987
CORRESPONDENCE DATA	
Fax Number:	(212)704-6288
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	2127046000
Email:	IPservicesNYC@troutman.com, rosalee.leeds@troutman.com
Correspondent Name:	TROUTMAN SANDERS LLP
Address Line 1:	875 THIRD AVENUE
Address Line 4:	NEW YORK, NEW YORK 10022
ATTORNEY DOCKET NUMBER:	250478.001655

NAME OF SUBMITTER:	ROSALEE LEEDS
SIGNATURE:	/Rosalee Leeds/
DATE SIGNED:	06/03/2019
Total Attachments: 3 source=1655_2_assignment-pat-47136-86#page3.tif source=1655_2_assignment-pat-47136-86#page4.tif source=1655_2_assignment-pat-47136-86#page5.tif	



**ASSIGNMENT
(Joint Inventors)**

Serial No. 13/026,070

Filed: February 11, 2011

Attorney Docket No. 31315/44241C

For good and valuable considerations, the receipt and sufficiency whereof are hereby acknowledged, we hereby assign to **BAXTER INTERNATIONAL INC.**, a corporation of Delaware, having a principal place of business at Deerfield, Illinois, its successors, legal representatives and assigns, and to **BAXTER HEALTHCARE S.A.**, a corporation of Switzerland, having a principal place of business at Glattpark (Opfikon), Switzerland, its successors, legal representatives and assigns (hereinafter jointly referred to as "assignee") the entire right, title and interest throughout the world, to the extent not previously assigned to assignee, in our invention or improvements in

TFPI INHIBITORS AND METHODS OF USE

and, effective as of the date of filing, in the above listed application(s) for Letters Patent therefor, executed by each of us individually, and any and all other patent applications in any and all countries which have been or may hereafter be filed, either solely or jointly with others, on said invention or improvements, and in any and all Letters Patent of any country which may be obtained on any of the said applications, and in any reissue or extension thereof and any applications that claim priority thereto, including any regional and national stage applications.

We hereby authorize and request the patent offices of all countries to issue to the said assignee all patents that may issue on said invention or improvements. We hereby authorize and request the attorneys of record in said application to insert in this assignment the date and serial number and docket number of said applications when officially known.

We warrant ourselves to be the owners of the interest herein assigned and to have the right to make this assignment; and further warrant that there are no outstanding prior assignments, licenses, or other rights to any person or entity other than the assignee in the interest herein assigned.

For said considerations we hereby agree, upon the request and at the expense of said assignee, its successors, legal representatives and assigns, to execute any and all divisional, continuation, and renewal applications for said invention or improvements, and any necessary oath or supplemental oath or affidavit relating thereto, and any application for the reissue or extension of any Letters Patent that may be granted upon said application, including any regional and national stage applications that claim priority thereto, that said assignee, its successors, legal representatives and assigns may deem necessary or expedient, and for the said considerations we further agree, upon the request of said assignee, its successors, legal representatives and assigns, in the event of said application or any continuation or division thereof, or Letters Patent issued thereon, or any reissue or application for the reissue thereof becoming involved in interference, to cooperate to the best of our ability with said assignee, its successors, legal representatives and assigns in the matters of preparing and executing the preliminary statement and giving and producing evidence in support thereof.

We further agree to perform, upon such request, any and all affirmative acts, including but not limited to execution of any and all documents deemed necessary or expedient by the said assignee or its successors, legal representatives or assigns, to obtain Letters Patent, and vest all rights therein hereby conveyed in the said assignee, its successors, legal representatives and assigns whereby said Letters Patent will be held and enjoyed by the said assignee, its successors, legal representatives and assigns to the end of the term for which said Letters Patent may be granted as fully and entirely as the same would have been held and enjoyed by us if this assignment and sale had not been made, and for the said considerations we hereby also assign to said assignee, its successors, legal representatives and assigns the entire right, title and interest in said invention or improvements for any and all foreign countries and the right of priority for patent and utility model applications in all countries arising under any applicable international convention for the protection of industrial property and/or any internal priority legislation of such countries, and we further agree upon the request of said assignee, its successors, legal representatives and assigns to execute any and all documents that shall be required to be executed in connection with any and all applications for foreign Letters Patent therefor, including the prosecution thereof, and to execute any and all documents necessary to invest title in said foreign applications and patents in said assignee.

WITNESS our hand and seal.

98723_3

Baxter

**Signature Sheet
(Joint Inventors)**

Serial No. 13/026,070

Filed: February 11, 2011

Attorney Docket No. 31315/44241C

TFPI INHIBITORS AND METHODS OF USE

Inventor Name: Michael DOCKAL

Inventor Name: Rudolf HARMANN

Date: April 29 2011

Date: 29.04.2011

Signature: [Signature]

Signature: [Signature]

Witness Name: Rudolf HARMANN

Witness Name: MICHAEL DOCKAL

Date: 29.04.2011

Date: April 29 2011

Signature: [Signature]

Signature: [Signature]

Inventor Name: Markus FRIES

Inventor Name: Friedrich SCHEIFLINGER

Date: 29.04.2011

Date: 09/05/11

Signature: [Signature]

Signature: [Signature]

Witness Name: KATERINA PROHASKA

Witness Name: Renate de Lellwa

Date: 29.04.2011

Date: 09/05/11

Signature: [Signature]

Signature: [Signature]

Baxter

*Signature Sheet
(Joint Inventors)*

Serial No. 13/026,970

Filed: February 11, 2011

Attorney Docket No. 31315/44241C

TFPI INHIBITORS AND METHODS OF USE

Inventor Name: Hartmut EHRlich

Date 10/05/2011

Signature 

Witness Name JLSE NONKUNGER

Date 10/05/2011

Signature 

50175_3